Contraceptive Drugs Market Size, Share, and Trends 2024 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Contraceptive Drugs Market 

5.1. COVID-19 Landscape: Contraceptive Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Contraceptive Drugs Market, By Product

8.1. Contraceptive Drugs Market, by Product, 2024-2033

8.1.1 Oral

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Lead Acid

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Intrauterine Devices (IUD)

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Condoms

8.1.4.1. Market Revenue and Forecast (2021-2033)

8.1.5. Vaginal Ring

8.1.5.1. Market Revenue and Forecast (2021-2033)

8.1.6. Subdermal Implants

8.1.6.1. Market Revenue and Forecast (2021-2033)

8.1.7. Injectable

8.1.7.1. Market Revenue and Forecast (2021-2033)

8.1.8. Others

8.1.8.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Contraceptive Drugs Market, By Distribution Channel

9.1. Contraceptive Drugs Market, by Distribution Channel, 2024-2033

9.1.1. Hospital Pharmacy

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Retail Pharmacy

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Clinics

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Online Channel

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. Public Channel & NGOs

9.1.5.1. Market Revenue and Forecast (2021-2033)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Contraceptive Drugs Market, By Age Group 

10.1. Contraceptive Drugs Market, by Age Group, 2024-2033

10.1.1. 15–24 years

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. 25–34 years

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. 35–44 years

10.1.3.1. Market Revenue and Forecast (2021-2033)

10.1.4. Above 44 years

10.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Contraceptive Drugs Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Product (2021-2033)

11.1.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.1.3. Market Revenue and Forecast, by Age Group (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.1.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.1.4.3. Market Revenue and Forecast, by Age Group (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.1.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.1.5.3. Market Revenue and Forecast, by Age Group (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.2.3. Market Revenue and Forecast, by Age Group (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.2.4.3. Market Revenue and Forecast, by Age Group (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.2.5.3. Market Revenue and Forecast, by Age Group (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.2.6.3. Market Revenue and Forecast, by Age Group (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.7.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.2.7.3. Market Revenue and Forecast, by Age Group (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.3.3. Market Revenue and Forecast, by Age Group (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.3.4.3. Market Revenue and Forecast, by Age Group (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.3.5.3. Market Revenue and Forecast, by Age Group (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.3.6.3. Market Revenue and Forecast, by Age Group (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.7.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.3.7.3. Market Revenue and Forecast, by Age Group (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.4.3. Market Revenue and Forecast, by Age Group (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.4.4.3. Market Revenue and Forecast, by Age Group (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.4.5.3. Market Revenue and Forecast, by Age Group (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.4.6.3. Market Revenue and Forecast, by Age Group (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.7.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.4.7.3. Market Revenue and Forecast, by Age Group (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.5.3. Market Revenue and Forecast, by Age Group (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.5.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.5.4.3. Market Revenue and Forecast, by Age Group (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.5.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

11.5.5.3. Market Revenue and Forecast, by Age Group (2021-2033)

Chapter 12. Company Profiles

12.1. Church & Dwight Co., Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Reckitt Benckiser Group Plc

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Veru, Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Organon Group of Companies

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Pfizer, Inc.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Teva Pharmaceutical Industries Ltd.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. The Cooper Companies, Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Mayer Laboratories, Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Agile Therapeutics

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. TherapeuticsmMD, Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms